Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
- PMID: 20030467
- DOI: 10.1592/phco.30.1.1
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
Abstract
Study objective: To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure.
Design: Prospective cohort study.
Setting: Two adult heart failure clinics.
Patients: Sixty-two adult (mean +/- SD age 54 +/- 16 yrs) aldosterone antagonist-naïve patients with heart failure.
Intervention: Patients received spironolactone 12.5 mg/day, titrated to 25 mg/day if tolerated.
Measurements and main results: Blood samples were obtained at baseline, 1 week after spironolactone initiation, and 1 week after spironolactone dose titration for assessment of baseline aldosterone level, serum chemistry, and angiotensinogen (AGT) c.-6G>A and p.M268T and mineralocorticoid receptor (NR3C2) c.215C>G and p.I180V genotypes. Patient characteristics, laboratory values, and genotypes were compared between those whose potassium levels increased by more than 0.5 mEq/L (15 patients) and those with lower potassium level elevations (47 patients) after spironolactone initiation and dose titration. Patients with a greater potassium level elevation had a higher mean +/- SD aldosterone concentration (178 +/- 92 vs 102 +/- 57 pg/ml, p=0.007) and NR3C2 215G allele frequency (50% vs 22%, p<0.01). Aldosterone concentrations positively correlated with diuretic dose (r=0.313, p=0.014) and negatively correlated with serum potassium level (r= -0.319, p=0.012). On regression analysis, factors predictive of potassium level increases greater than 0.5 mEq/L with spironolactone were aldosterone level greater than 150 pg/ml (odds ratio [OR] 30, 95% confidence interval [CI] 3.2-287] and NR3C2 215G carrier status (OR 17, 95% CI 1.6-167).
Conclusion: Our data suggest that potassium should be monitored with particular caution when spironolactone is started in patients with heart failure who have evidence of elevated aldosterone levels, such as high diuretic requirements, or the NR3C2 215G allele.
Similar articles
-
Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.ESC Heart Fail. 2018 Jun;5(3):257-266. doi: 10.1002/ehf2.12265. Epub 2018 Jan 25. ESC Heart Fail. 2018. PMID: 29369537 Free PMC article. Clinical Trial.
-
Race influences the safety and efficacy of spironolactone in severe heart failure.Circ Heart Fail. 2013 Sep 1;6(5):970-6. doi: 10.1161/CIRCHEARTFAILURE.113.000530. Epub 2013 Aug 12. Circ Heart Fail. 2013. PMID: 23940307 Clinical Trial.
-
Racial differences in potassium response to spironolactone in heart failure.Congest Heart Fail. 2006 Jul-Aug;12(4):200-5. doi: 10.1111/j.1527-5299.2006.05502.x. Congest Heart Fail. 2006. PMID: 16894278 Clinical Trial.
-
[Aldosterone and its antagonists in heart failure].Presse Med. 2003 Jan 18;32(2):79-87. Presse Med. 2003. PMID: 12653034 Review. French.
-
[Diuretic therapy in congestive heart failure--new views on spironolactone therapy].Ther Umsch. 2000 Jun;57(6):374-9. doi: 10.1024/0040-5930.57.6.374. Ther Umsch. 2000. PMID: 10894022 Review. German.
Cited by
-
Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction.Biochim Biophys Acta Mol Basis Dis. 2017 Aug;1863(8):2012-2018. doi: 10.1016/j.bbadis.2016.10.025. Epub 2016 Oct 29. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 27989961 Free PMC article. Review.
-
Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.Hypertension. 2018 Sep;72(3):537-548. doi: 10.1161/HYPERTENSIONAHA.118.11065. Hypertension. 2018. PMID: 29987104 Free PMC article. Review. No abstract available.
-
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.Eur Heart J. 2011 Apr;32(7):820-8. doi: 10.1093/eurheartj/ehq502. Epub 2011 Jan 5. Eur Heart J. 2011. PMID: 21208974 Free PMC article. Clinical Trial.
-
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.Pharmacotherapy. 2021 Dec;41(12):978-987. doi: 10.1002/phar.2626. Epub 2021 Oct 12. Pharmacotherapy. 2021. PMID: 34569641 Free PMC article. Clinical Trial.
-
Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure.PLoS One. 2013 Jul 30;8(7):e71268. doi: 10.1371/journal.pone.0071268. Print 2013. PLoS One. 2013. PMID: 23936266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous